Prognosis of pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines

被引:389
作者
McLaughlin, VV
Presberg, KW
Doyle, RL
Abman, SH
McCrory, DC
Fortin, T
Ahearn, G
机构
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Univ Colorado, Childrens Hosp, Hlth Sci Ctr, Denver, CO 80202 USA
[5] Duke Univ, Med Ctr, Durham, CA USA
关键词
cardiopulmonary exercise testing; echocardiography; epoprostenol; functional class; hemodynamics; prognosis; pulmonary hypertension; 6 min walk test; survival; vasoreactivity;
D O I
10.1378/chest.126.1_suppl.78S
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Although idiopathic pulmonary arterial hypertension is perceived as a progressive disease with a uniformly poor outcome, the natural history of disease is heterogeneous, with some patients dying within months of diagnosis and others living for decades. The course of the disease has also been altered by advances in medical therapies. The outcome of patients with other types of pulmonary arterial hypertension (PAH) has been less well characterized. Assessment of prognosis of such patients is important, as it influences both medical therapy and referral for transplantation. This chapter will provide evidence based recommendations to assess the prognosis of patients with PAH.
引用
收藏
页码:78S / 92S
页数:15
相关论文
共 45 条
[1]   Primary pulmonary hypertension in Israel - A national survey [J].
Appelbaum, L ;
Yigla, M ;
Bendayan, D ;
Reichart, N ;
Fink, G ;
Priel, I ;
Schwartz, Y ;
Richman, P ;
Picard, E ;
Goldman, S ;
Kramer, MR .
CHEST, 2001, 119 (06) :1801-1806
[2]   Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+
[3]   Vasodilator therapy for primary pulmonary hypertension in children [J].
Barst, RJ ;
Maislin, G ;
Fishman, AP .
CIRCULATION, 1999, 99 (09) :1197-1208
[4]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[5]   SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION WITH LONG-TERM CONTINUOUS INTRAVENOUS PROSTACYCLIN [J].
BARST, RJ ;
RUBIN, LJ ;
MCGOON, MD ;
CALDWELL, EJ ;
LONG, WA ;
LEVY, PS .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (06) :409-415
[6]   The prognostic role of the ECG in primary pulmonary hypertension [J].
Bossone, E ;
Paciocco, G ;
Iarussi, D ;
Agretto, A ;
Iacono, A ;
Gillespie, BW ;
Rubenfire, M .
CHEST, 2002, 121 (02) :513-518
[7]  
Chun Kook-Jin, 2001, Korean Journal of Internal Medicine, V16, P75
[8]  
Conte JV, 1998, J HEART LUNG TRANSPL, V17, P679
[9]   SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY [J].
DALONZO, GE ;
BARST, RJ ;
AYRES, SM ;
BERGOFSKY, EH ;
BRUNDAGE, BH ;
DETRE, KM ;
FISHMAN, AP ;
GOLDRING, RM ;
GROVES, BM ;
KERNIS, JT ;
LEVY, PS ;
PIETRA, GG ;
REID, LM ;
REEVES, JT ;
RICH, S ;
VREIM, CE ;
WILLIAMS, GW ;
WU, M .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) :343-349
[10]   TWO-DIMENSIONAL AND DOPPLER-ECHOCARDIOGRAPHIC AND CARDIAC-CATHETERIZATION CORRELATES OF SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION [J].
EYSMANN, SB ;
PALEVSKY, HI ;
REICHEK, N ;
HACKNEY, K ;
DOUGLAS, PS .
CIRCULATION, 1989, 80 (02) :353-360